Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Intermountain's Edited Cancer Panel Reducing Rate of Tests Rejected Due to Insufficient Samples

Intermountain's Edited Cancer Panel Reducing Rate of Tests Rejected Due to Insufficient Samples

May 30, 2017
|
Turna Ray
Premium

This article previously described the ICG100 Onco Focus Panel as a next-generation sequencing test based on an Intermountain press release that erroneously described it as such. The panel uses Agena Bioscience's MassARRAY system, and this article has been updated to reflect that. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Another Cold Case Arrest

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

Circumventing that Pesky Poison

NPR reports that some insect pests are now becoming resistant to Bt crops.

Not Convened

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

Nature Papers Describe Future Path for Human Genomic Research, Method to Analyze RNA Structure With Nanopore Sequencing, More

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
10
Featured Webinar

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

Nov
18
Featured Webinar

Rapid WGS: How Rady Children’s Institute Is Increasing Diagnostic Yield and Improving Outcomes

Sponsored by
Genomenon

Rapid whole-genome sequencing (rWGS) is an emerging method that can provide molecular diagnosis in time to alter acute medical or surgical management and improve outcomes in acutely ill children.

What's Popular?

In Molecular Diagnostics

  1. UPDATE: Biocartis, Exact Sciences Terminate Oncotype DX Agreement

  2. Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

  3. Illumina's ExpansionHunter Software Shows Clinical Promise for STR Expansions

    Premium

  4. Exact Sciences Aiming to Make Pan-Cancer Blood Screening Part of Standard Medical Care

    Premium

  5. Biodesix Prices $72M IPO

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.